TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31542980
Drug: Unexpected nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unexpected nicotine administration
Study: 25291152
Drug: Racemic metoprolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Racemic metoprolol tartrate 100 mg oral dose
Study: 19182682
Drug: Antidyspeptic drugs
Normalized name: Listerine Antiseptic
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidyspeptic drugs usage
Study: 2036693
Drug: 0.01 mg.kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.01 mg.kg‐1 atropine iv one minute before fentanyl (Group 3)
Study: 2036693
Drug: 0.2 mg.kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg.kg‐1 morphine im one hour before fentanyl (Group 4)
Study: 2036693
Drug: 7.5 mg
Normalized name: biotin 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg midazolam po one hour before fentanyl (Group 5)
Study: 7272896
Drug: Protected environment-prophylactic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protected environment-prophylactic antibiotic (PEPA)
Study: 9861551
Drug: Immediate-release methylphenidate
Normalized name: methylphenidate Extended Release Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release methylphenidate (IR; 20-40 mg)
Study: 9861551
Drug: Sustained-release methylphenidate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release methylphenidate (SR; 20-40 mg)
Study: 30907346
Drug: Integrated sandplay
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Integrated sandplay therapy in addition to routine training
Study: 19183412
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (bromfenac and betamethasone)
Study: 9855322
Drug: Aminophylline 350
Normalized name: aminophylline 350 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminophylline 350 mg
Study: 7861791
Drug: Ethanol (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol (1.0 g/kg, divided into two equal doses given 75 minutes apart)
Study: 21972626
Drug: Electroacupuncture and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroacupuncture and acupoint injection with Neostigmine (in addition to conventional western medicine)
Study: 21972626
Drug: Conventional western
Normalized name: western larch pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional western medicine (control group)
Study: 21972626
Drug: Electroacupuncture and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroacupuncture and acupoint injection with Neostigmine
Study: 12135284
Drug: Liposomal amphotericin
Normalized name: Liposomal amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liposomal amphotericin B (AmBisome) at cumulative doses of 3.75 mg/kg for 5 days
Study: 12135284
Drug: Liposomal amphotericin
Normalized name: Liposomal amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liposomal amphotericin B (AmBisome) at cumulative doses of 7.5 mg/kg for 5 days
Study: 12135284
Drug: Liposomal amphotericin
Normalized name: Liposomal amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liposomal amphotericin B (AmBisome) at cumulative doses of 15.0 mg/kg for 5 days
Study: 31255890
Drug: Standard multimodal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard multimodal analgesia (routine paracetamol and tramadol PCA in addition to diclophenac sodium as rescue analgesia)
Study: 26401826
Drug: 2‐DeNT Oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2‐DeNT Oral Topical Powder
Study: 25329470
Drug: Participatory women's
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participatory women's health groups intervention with monthly meetings and a participatory learning and action cycle.
Study: 9234028
Drug: Intervention group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention group (60 g breakfast cereal daily with semi-skimmed milk)
Study: 8383096
Drug: Ketoconazole 400
Normalized name: ketoconazole 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoconazole 400 mg daily for 7 days
Study: 8383096
Drug: Itraconazole 200
Normalized name: itraconazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole 200 mg orally, or clotrimazole 200 mg intravaginally, twice weekly for six months
Study: 3770039
Drug: Pneumococcal vaccine
Normalized name: PNEUMOCOCCAL VACCINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pneumococcal vaccine (Moniarix)
Study: 21143869
Drug: Procalcitonin-guided treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Procalcitonin-guided treatment
Study: 18607265
Drug: 5 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g of rice cereal added to 100 mL standard formula (group B)
Study: 18607265
Drug: Formula manufactured
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formula manufactured with bean gum as a thickening agent (group C)
Study: 10918827
Drug: Treatment in
Normalized name: Other agents for local oral treatment in ATC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment in a stroke unit
Study: 8878223
Drug: Penicillin V
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Penicillin V (three times daily for 10 days)
Study: 1457110
Drug: Fresh gas
Normalized name: Peroxi-Fresh
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fresh gas flow at N2O 1 L/min and O2 0.6 L/min (Group 1)
Study: 1457110
Drug: Fresh gas
Normalized name: Peroxi-Fresh
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fresh gas flow at N2O 0.5 L/min and O2 0.5 L/min (Group 2)
Study: 3888246
Drug: Oral methoxsalen
Normalized name: Methoxsalen
DrugBank: Methoxsalen (DB00553)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral methoxsalen (13 cases)
Study: 3888246
Drug: 1% methoxsalen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% methoxsalen cream (33 cases)
Study: 31861038
Drug: Intravenous cannula
Normalized name: CANNULA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous cannula
Study: 29399799
Drug: Intravenous plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous plus intra-articular tranexamic acid (20 mg/kg intravenous and 3.0 g intra-articular)
Study: 29399799
Drug: Intra-articular tranexamic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular tranexamic acid alone (3.0 g intra-articular and normal saline intravenous)
Study: 29399799
Drug: Intravenous plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous plus intra-articular tranexamic acid
Study: 17074952
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual plus contingency management
Study: 15284214
Drug: Estradiol 1
Normalized name: estradiol 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estradiol 1 mg + Dydrogesterone 5 mg (group D)
Study: 15284214
Drug: Estradiol 1
Normalized name: estradiol 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estradiol 1 mg + Norethisterone 0.5 mg (group N)
Study: 11716200
Drug: Lactose (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactose (doses ranging from 6.25 mg to 100 mg)
Study: 11716200
Drug: Lactose (higher
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactose (higher than normal clinical doses)
Study: 22943662
Drug: 200 mg/day
Normalized name: alpelisib 200 mg/day (200 mg x 1) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg/day ketoprofen
Study: 22943662
Drug: 300 mg/day
Normalized name: alpelisib 300 mg/day (150 mg x 2) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg/day ketoprofen
Study: 24301242
Drug: Desoximetasone spray
Normalized name: desoximetasone Topical Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desoximetasone spray 0.25% twice daily
Study: 24301242
Drug: Vehicle spray
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle spray twice daily
Study: 12166347
Drug: Ibuprofen up
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen up to 1200 mg daily for 1-7 days
Study: 12166347
Drug: Paracetamol up
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol up to 3000 mg daily for 1-7 days
Study: 12166347
Drug: Aspirin up
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin up to 3000 mg daily for 1-7 days
Study: 7988577
Drug: Epidural infusion
Normalized name: epidural administration set EPIDURAL INFUSION SETS-PARAPHERNALIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural infusion of 0.083 mg ml-1 of diamorphine in 0.167% bupivacaine
Study: 7988577
Drug: Epidural infusion
Normalized name: epidural administration set EPIDURAL INFUSION SETS-PARAPHERNALIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural infusion of 0.083 mg ml-1 of diamorphine in 0.9% NaCl solution (control)
Study: 2925353
Drug: Mazindol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mazindol (2 mg, oral administration)
Study: 11695211
Drug: New dentifrice
Approvals — FDA: no, EMA: no, PMDA: no
Description: New dentifrice formulation variant (Colgate Total Plus Whitening Toothpaste)
Study: 29198062
Drug: Heparin in
Normalized name: heparin Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin in saline (H)
Study: 29198062
Drug: Heparin and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin and albumin in saline (HA)
Study: 29198062
Drug: Heparin and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin and albumin in combination with a citrate-containing dialysate (HAC)
Study: 29198062
Drug: Saline and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline and using heparin-coated filters (Evodial®)
Study: 25080293
Drug: IGF1 titration
Normalized name: apomorphine
DrugBank: Apomorphine (DB00714)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IGF1 titration
Study: 25080293
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose (67 μg/kg per day)
Study: 25080293
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose (35 μg/kg per day)
Study: 18525041
Drug: Aliskiren (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aliskiren (150 mg daily for 3 months, then 300 mg daily for 3 months)
Study: 12025250
Drug: 0.5% ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% ropivacaine (12.5 mg)
Study: 12025250
Drug: 0.5% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% bupivacaine (12.5 mg)
Study: 10496549
Drug: Age and
Normalized name: wound drainage and fistula management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Age and number of medications
Study: 2140554
Drug: Dopamine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine infusion (1.5 micrograms/Kg/min for 60 min)
Study: 7004257
Drug: Self-administered intravenous
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-administered intravenous pethidine (0.25 mg/kg available at 10-min intervals)
Study: 7004257
Drug: Intramuscular pethidine
Normalized name: pethidine
DrugBank: Meperidine (DB00454)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular pethidine (150 mg, repeated if necessary)
Study: 26863353
Drug: Caplacizumab (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caplacizumab (10 mg daily)
Study: 25002290
Drug: Levothyroxine (L‐T4)
Normalized name: L-T4
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Levothyroxine (L‐T4) adjunctive treatment
Study: 11465523
Drug: Doxepin (25-50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxepin (25-50 mg)
Study: 9604124
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg artemisinin
Study: 9604124
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg artemisinin
Study: 9604124
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg artemisinin
Study: 9604124
Drug: Artemisinin (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artemisinin (all doses)
Study: 8067230
Drug: Morphine/bupivacaine (MB)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine/bupivacaine (MB) - morphine at 0.2 mg.h‐1 and bupivacaine at 10 mg.h‐1 for the first 24 h, then 5 mg.h‐1 for the second 24 h
Study: 8067230
Drug: Fentanyl/bupivacaine (FB)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl/bupivacaine (FB) - fentanyl at 20 micrograms.h‐1 and bupivacaine at 10 mg.h‐1 for the first 24 h, then 5 mg.h‐1 for the second 24 h
Study: 28454801
Drug: Anacetrapib 100mg
Normalized name: Anacetrapib
DrugBank: Anacetrapib (DB06630)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anacetrapib 100mg daily
Study: 23727422
Drug: HBsAg-1018 (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBsAg-1018 (20 mcg rHBsAg + 3000 mcg 1018, a toll‐like receptor 9 agonist) given at 0, 4, and 24 weeks
Study: 23727422
Drug: HBsAg-Eng (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBsAg-Eng (4 double-doses of 2×20 mcg rHBsAg + 500 mcg alum given at 0, 4, 8, and 24 weeks)
Study: 19129506
Drug: Antiplatelet medications
Normalized name: simethicone
DrugBank: Simethicone (DB09512)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiplatelet medications at ICH onset
Study: 9088076
Drug: Intravenous Epoetin
Normalized name: Epoetin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Epoetin alfa (300 IU/kg twice weekly for 3 weeks)
Study: 9088076
Drug: Subcutaneous Epoetin
Normalized name: Epoetin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous Epoetin alfa (100 IU/kg twice weekly for 3 weeks plus an i.v. bolus of 200 IU/kg at the first visit)
Study: 3742316
Drug: Group A
Normalized name: Blood group A IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A - ten per cent methohexitone, 25 mg X kg‐1 (n = 20)
Study: 3742316
Drug: Group B
Normalized name: Blood group B IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B - ten per cent methohexitone, 15 mg X kg‐1 (n = 20)
Study: 3742316
Drug: Group C
Normalized name: STREPTOCOCCUS ANTIGEN (GROUP C)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group C - one per cent methohexitone, 15 mg X kg‐1 (n = 20)
Study: 3742316
Drug: Group A
Normalized name: Blood group A IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A - ten per cent methohexitone, 25 mg X kg‐1
Study: 3742316
Drug: Group C
Normalized name: STREPTOCOCCUS ANTIGEN (GROUP C)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group C - one per cent methohexitone, 15 mg X kg‐1
Study: 29550045
Drug: Ticagrelor (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticagrelor (90 mg twice daily for 6 months) + Aspirin (81 mg for 6 months)
Study: 29550045
Drug: Clopidogrel (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (75 mg once daily for 1 month) + Aspirin (81 mg for 6 months)
Study: 19936713
Drug: Control day
Normalized name: Avobenzone 30 mg in 1 mL / Octinoxate 75 mg in 1 mL TOPICAL LOTION [Oil-Control Day SPF 15]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control day (air inhalation)
Study: 15653003
Drug: 17beta-estradiol and
Normalized name: Estradiol-17beta
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 17beta-estradiol and levonorgestrel (both doses)
Study: 10402244
Drug: Tamoxifen (TAM)
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tamoxifen (TAM) as a single agent
Study: 10402244
Drug: Tamoxifen (TAM)
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tamoxifen (TAM) in combination with dacarbazine
Study: 10402244
Drug: Tamoxifen (TAM)
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tamoxifen (TAM) in combination with various cytotoxic agents
Study: 10402244
Drug: Tamoxifen (TAM)
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tamoxifen (TAM) combined with cisplatin at high doses
Study: 1661657
Drug: L-arginine free
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine free base (5 mumol/min)
Study: 1661657
Drug: L-arginine hydrochloride
DrugBank: L-arginine (DB17289)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine hydrochloride (5 mumol/min)
Study: 1661657
Drug: L-arginine free
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine free base (160 mumol/min)
Study: 1661657
Drug: L-arginine hydrochloride
DrugBank: L-arginine (DB17289)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine hydrochloride (160 mumol/min)
Study: 6136292
Drug: Clobazam (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clobazam (10 mg twice a day)
Study: 6136292
Drug: Lorazepam (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam (1 mg twice a day)
Study: 3902533
Drug: Flunisolide inhalation,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunisolide inhalation, 500 mcg twice daily
Study: 3902533
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate inhaler, 100 mcg four times daily
Study: 26987975
Drug: V158866 (5-300
Approvals — FDA: no, EMA: no, PMDA: no
Description: V158866 (5-300 mg single doses; 50-500 mg repeated doses)
Study: 26987975
Drug: V158866 (300-500
Approvals — FDA: no, EMA: no, PMDA: no
Description: V158866 (300-500 mg/day)
Study: 23494104
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no LLLT or ozone therapy)
Study: 19793142
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (LMWH) - enoxaparin 1 mg/kg bd
Study: 16901550
Drug: 1-deamino 8-D-arginine
Normalized name: 1-deamino-8-D-arginine vasopressin
DrugBank: Desmopressin (DB00035)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1-deamino 8-D-arginine vasopressin (DDAVP) spray
Study: 26599707
Drug: Diesel exhaust
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diesel exhaust (200 μg/m(3) PM2.5)
Study: 22595974
Drug: Oral absorbable
Normalized name: COLLAGEN HEMOSTAT,ABSORBABLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral absorbable fat-soluble vitamin formulation (OAFSV)
Study: 19940231
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg Rd (single dose)
Study: 19940231
Drug: 45 mg
Normalized name: lutein 45 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 45 mg Rd (single dose)
Study: 19940231
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg Rd (single dose)
Study: 19940231
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg Rd (multiple dose)
Study: 18567166
Drug: Metronidazole plus
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metronidazole plus Amoxicillin
Study: 7782581
Drug: CO2 laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: CO2 laser treatment for cervical intraepithelial neoplasia
Study: 321991
Drug: Dimethothiazine, 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dimethothiazine, 60 mg/day for 2 to 3-4 months
Study: 23168581
Drug: ARA 290
Normalized name: 2-fluoro ARA-A
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARA 290 (2 mg, intravenous, three times weekly for 4 weeks)
Study: 20164296
Drug: Teriparatide 40
Normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Teriparatide 40 microg sc daily
Study: 18478937
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose thymopentin (10 mg/d) combined with trans-artery chemoembolization (TACE) with oxaliplatin 150 mg, pharmorubicin 50 mg, 5‐Fu 750 mg, CF 300 mg and lipiodol 20 ml.
Study: 18478937
Drug: Trans-artery chemoembolization
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trans-artery chemoembolization (TACE) with oxaliplatin 150 mg, pharmorubicin 50 mg, 5‐Fu 750 mg, CF 300 mg and lipiodol 20 ml.
Study: 18478937
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose thymopentin (10 mg/d) combined with TACE.
Study: 12152996
Drug: Gemcitabine 1250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine 1250 mg/mq (days 1, 8 and 15) as a single agent for 3 monthly courses
Study: 12152996
Drug: Gemcitabine 1000
Normalized name: gemcitabine 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine 1000 mg/mq (days 1, 8 and 15) plus cisplatin 80 mg/mq (day 1)
Study: 12152996
Drug: Time to
Normalized name: Overtime Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Time to treatment failure (TTF)
Study: 10622647
Drug: Rocuronium (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium (both doses)
Study: 8622102
Drug: Isepamicin 8
Normalized name: isepamicin
DrugBank: Isepamicin (DB13540)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isepamicin 8 or 15 mg/kg once daily
Study: 6893580
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg sublingual molsidomine
Study: 24383496
Drug: Antibiotic-impregnated VPS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic-impregnated VPS
Study: 21967645
Drug: Ticagrelor 270
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor 270 mg (3×90 mg tablets) after a 10-h overnight fast
Study: 21967645
Drug: Ticagrelor 270
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor 270 mg (3×90 mg tablets) after a standard high-fat, high-calorie breakfast
Study: 19296870
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 supplementation (50 microg or 2000 IU daily for 12 weeks)
Study: 17469042
Drug: Pioglitazone (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone (30 mg per day)
Study: 11989392
Drug: Exogenous hyaluronan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exogenous hyaluronan administration
Study: 1399475
Drug: Conventional intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional intravenous cannulas
Study: 3540879
Drug: Propoxyphene HCl
Normalized name: propoxyphene HCl
DrugBank: Dextropropoxyphene (DB00647)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propoxyphene HCl 65 mg
Study: 3540879
Drug: Aspirin 650
Normalized name: aspirin 650 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 650 mg with codeine 60 mg